Gliadin p31-43 TFA 是一种未消化的麦醇溶蛋白肽,可诱导肠道内的先天性免疫反应并干扰内吞运输。Gliadin p31-43 TFA 可用于乳糜泻的研究。
生物活性 |
Gliadin p31-43 TFA is an undigested gliadin peptide. Gliadin p31-43 TFA induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 TFA can be used for celiac disease research[1][2].
|
体外研究 (In Vitro) |
Gliadin p31-43 (100 μg/mL; 30 minutes-6 hours) treatment induces the MyD88/TLR7 complexes, and activates downstream signalling by activating MAPKs, ERK, JNK and p38). Gliadin p31-43 increases the levels of the phosphorylated forms of pY-ERK, JNK (pY-JNK) and p38 (pY-p38)[1]. Gliadin p31-43 treatment increases NF-κB phosphorylation in CaCo-2 cells from 0.45 in control cells to 0.86. Gliadin p31-43 treatment induces a significant increase in levels of the MxA protein. The levels of the IFN-α 7 and 17 mRNAs are also analysed after Gliadin p31-43 treatment[1]. In CaCo-2 cells, Gliadin p31-43 localizes to the early endosomes and delays vesicular trafficking. Gliadin p31-43 interferes with the correct localization of the growth factor regulated tyrosine kinase substrate (HRS) to early endosomes, delaying the maturation of the endocytic vesicles[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis[1]
Cell Line: |
CaCo-2 cells |
Concentration: |
100 μg/mL |
Incubation Time: |
30 minutes, 3 hours, 6 hours |
Result: |
Showed the increase in formation of the MyD88/TLR7 complex, and increased in the level of TLR7. |
|
体内研究 (In Vivo) |
Gliadin p31-43 (10 μg; intraluminally injection) shows a sequence-specific spontaneous ability to form structured oligomers and aggregates in vitro and induced activation of the apoptosis-associated speck-like (ASC) complex[2]. The increment of IL-1β indicates the activation of the inflammasome caspase-1 pathway in the small intestine mucosa by oral administration of Gliadin p31-43 (20 μg) in wild type C57Bl/6 mice. Gliadin p31-43 has an intrinsic propensity to form oligomers which trigger the NLRP3 inflammasome[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
|
分子量 |
|
Formula |
|
Sequence Shortening |
|
运输条件 |
Room temperature in continental US; may vary elsewhere.
|
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
Solvent Solubility |
In Vitro:;
H2O
Peptide Solubility and Storage Guidelines:
1.;;Calculate the length of the peptide.
2.;;Calculate the overall charge of the entire peptide according to the following table:
; |
Contents |
Assign value |
Acidic amino acid |
Asp (D), Glu (E), and the C-terminal -COOH. |
-1 |
Basic amino acid |
Arg (R), Lys (K), His (H), and the N-terminal -NH2 |
+1 |
Neutral amino acid |
Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) |
0 |
3.;;Recommended solution:
Overall charge of peptide |
Details |
Negative (lt;0) |
1.;;Try to dissolve the peptide in water first. 2.;;If water fails, add NH4OH (lt;50 μL). 3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide. |
Positive (gt;0) |
1.;;Try to dissolve the peptide in water first. 2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO. |
Zero (=0) |
1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration. |
|
参考文献 |
-
[1]. Merlin Nanayakkara, et al. P31-43, an undigested gliadin peptide, mimics and enhances the innate immune response to viruses and interferes with endocytic trafficking: a role in celiac disease. Sci Rep. 2018 Jul 17;8(1):10821.
[2]. María Florencia Gómez Castro, et al. p31-43 Gliadin Peptide Forms Oligomers and Induces NLRP3 Inflammasome/Caspase 1- Dependent Mucosal Damage in Small Intestine. Front Immunol. 2019 Jan 30;10:31.
|